Related Experiment Video
Updated: Apr 29, 2026
Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
Published on: June 21, 2015
In the war against solid tumors arsenic trioxide needs partners
Pochi R Subbarayan1, Bach Ardalan
1Department of Medicine, University of Miami Miller School of Medicine, 1550 NW 10th Avenue, FOX 431A, Miami, FL, 33136, USA.
Abstract:
In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
Insights
Arsenic trioxide (ATO) shows limited efficacy alone in solid tumors but demonstrates therapeutic benefit when combined with other agents. Further research into ATO
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Arsenic trioxide (ATO) is recognized for its therapeutic potential in acute promyelocytic leukemia (APL).
- ATO's efficacy in other hematological and solid tumor malignancies is under investigation.
- Single-agent ATO has shown limited benefit in solid tumors.
Purpose of the Study:
- To summarize clinical trial outcomes of arsenic trioxide (ATO) in solid tumors.
- To review ATO's efficacy as a single agent and in combination therapy.
- To explore ATO's potential mechanisms as a chemosensitizer in combination treatments.
Main Methods:
- Review of clinical trial data for arsenic trioxide (ATO) in solid tumor patients.
- Analysis of outcomes for ATO used as a single agent versus in combination.
- Literature review of potential mechanisms of ATO as a chemosensitizer.
Main Results:
- Arsenic trioxide (ATO) as a single agent did not provide significant benefit for solid tumors.
- Combination therapy involving ATO showed emerging treatment benefits in solid tumors.
- ATO may enhance the efficacy of chemotherapy when used in combination.
Conclusions:
- Arsenic trioxide (ATO) is not effective as a standalone treatment for solid tumors.
- ATO shows promise as a chemosensitizer in combination therapies for solid tumors.
- Clinical investigators are encouraged to rationally combine ATO with other agents for solid tumor treatment.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Pharmaceutical Poisoning: Treatment Strategies
02:56Treatment Resistant Cancers
01:26Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...